Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
February 27, 2020
Earnings Call Speaker Segments
Jennifer Ruddock
executiveThanks, Crystal. Hello, everyone, and I appreciate you being with us this afternoon. Joining us today are Howard Robin, who serves as our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, who leads our R&D efforts; and Dr. Wei Lin, who oversees Development. During this call, we anticipate delivering forward-looking statements about our business, among them clinical trial results, the timing of and plans for upcoming clinical trials, when and how future clinical data will be presented at medical meetings, what our drug candidates might be able to treat, what we expect and intend regarding health authority regulatory actions and decisions, financial guidance, and several other statements concerning where our business is headed. Since these statements concern the future, they come with inherent uncertainties and risks that are hard to foresee, and a great many of them lie beyond our control. Key risks and uncertainties appear in our Form 10-Q, filed on November 7, 2019, which you can find at sec.gov. We assume no duty to revise any of these statements, whether because of new information, later developments, or any other reason. A webcast of today's call will be posted on the IR page of Nektar's website, nektar.com; and now I'll turn things over to Howard Robin, our President and CEO. Howard?
Howard Robin
executiveThanks, Jennifer, and I appreciate all of you being here on the call today. During this call, we're going to give you an update on the compounds in our pipeline, covering our IO pipeline candidates — Nektar IL-2, IL-15, and the TLR agonist — along with NKTR-358, our immunology program. We'll also go over the milestones we have planned for these programs coming up and share our financial guidance for 2020. However, before I get into the progress we achieved across our IO and immunology portfolio, I want to spend a moment on a few challenges from this year that fall outside the main focus of our pipeline. Let me begin with NKTR-181. As all of you are aware, last month we reached a strategic decision to pull the NDA for NKTR-181. The NKTR-181 ADCOM was the first among several that week that came out negative for the opioid class, and those discussions made it obvious that the bar any opioid compound must clear for approval sits far higher than what past approvals had established. On top of that, in the period since we filed our NDA, the liability surrounding the opioid class has turned into a major consideration, with many lawsuits brought against manufacturers and distributors of opioids. Given every one of these factors, we reached a business decision that no further investment could be justified for a medicine in this class, since doing so would have meant sacrificing important developmental work on our immuno-oncology pipeline. Looking back at the successful development efforts we carried out for this program, I want to express thanks to our team for their hard work, and to the patients and physicians who took part in our clinical trials, a few of whom came to speak at the ADCOM. This decision was not one we took lightly, but we believe it is the right action as we concentrate on advancing our IO and immunology pipeline. Second, as you're aware, we had been running the ATTAIN study for ONZEALD, our chemotherapy agent, in advanced breast cancer patients who also have brain metastases, comparing ONZEALD against a chemo agent of choice in those patients. A former partnership with Daiichi Sankyo was partially funding the ATTAIN study. You'll remember that the ATTAIN study's design was based on a doubling of survival observed in a subset of patients from the earlier BEACON study of ONZEALD in advanced breast cancer patients with brain mets, relative to chemotherapy of physician's choice. Late last week, the primary analysis of the ATTAIN study was finished. And although ONZEALD did at least as well as the physician's choice standard of care for PFS and OS, the study endpoint of improvement in overall survival was not met. Consequently, we plan no further clinical work on ONZEALD, and we are grateful to the patients and their families who took part in the ATTAIN study. With these actions now behind us, our company is highly focused on the core areas of immuno-oncology and immunology, where we believe we have the potential to create transformative medicines for patients. In our immuno-oncology pipeline, we have a lot that sets us apart: two potent cytokine programs — BEMPEG for IL-2 and NTKR-255 for IL-15 — plus a small molecule TLR agonist program. Thanks to this distinctive lineup, we can pursue possibilities across solid tumors as well as liquid tumors. Over in immunology, NKTR-358 is moving forward into a number of clinical trials covering various autoimmune conditions, beginning with lupus, atopic dermatitis, and psoriasis, and I'll share more details on those later during this call. Let me begin with BEMPEG, which is our IL-2 pathway program and a T cell stimulator. Earlier in the year, we disclosed a revised collaboration deal with BMS, our partner. Under that new joint development plan, we broadened the BMS and Nektar active Registrational Programs for the combination of BEMPEG plus NIVO from the 3 studies already underway to 7 studies now, in first-line and adjuvant settings, spanning 4 tumor types and involving over 3,000 patients. This new Registrational Program expands on the opportunity in melanoma, bladder cancer, and renal cell carcinoma, and it adds plans for a Phase II study in first-line non-small cell lung cancer. Beyond the 3 ongoing Registrational Trials — in first-line metastatic melanoma, first-line cis-ineligible metastatic bladder cancer, and first-line metastatic RCC — we have already started a new Phase III study in muscle-invasive bladder cancer, and we are kicking off a Phase III study in adjuvant melanoma. In a moment, I'll have Wei walk through the design of these new Phase III studies. When it comes to the economics of the revised agreement, they demonstrate BMS's ongoing dedication to the collaboration. Broadly speaking, BMS's portion of clinical costs under the new joint development plan tied to the 7 studies comes to roughly $1.2 billion. There were also certain improvements to the economics on Nektar's side, delivering extra and faster near-term milestone payments. That covers a $25 million accelerated milestone payment we got during Q1 of this year when the MIBC study began. It also covers a new $25 million milestone for Nektar when the adjuvant melanoma study starts, which we anticipate happening in Q3 of this year. On top of that, the new agreement provides a $75 million accelerated milestone payment when the first Phase III Registrational non-small cell lung cancer study with NIVO begins. All other economics stay as they were. BMS covers 2/3 of the development cost, while Nektar puts in 1/3. Nektar records global revenues. The profit split is 65% to Nektar and 35% to BMS. We are also due $650 million in total milestone payments when BEMPEG first wins approvals in the U.S., Europe, and Japan, followed by $260 million for each of the next 3 approved indications for BEMPEG. As a lot of you are aware, BMS right now is enrolling patients in our Registrational Trial in first-line metastatic melanoma, and every investigator site is up and running at this point. In the prior year, we secured an FDA breakthrough therapy designation for BEMPEG plus NIVO among patients suffering from metastatic melanoma, which was supported by favorable results, including the complete response rate from our PIVOT-02 trial. The Phase III trial now enrolling in that setting has three endpoints: ORR, PFS and OS. Right now, the earliest projected timeline for hitting the follow-up duration required on the patient count needed for the initial interim ORR endpoint is the close of Q4 2020, this year. Approximately 6 to 7 months afterward is when the PFS endpoint is expected. However, bear in mind that this is event-driven, so the timing may shift; for both OOR and PFS, a blinded independent radiology review will analyze the results. Thus, also remember that this process will impact the timing for finishing any data analysis. Consequently, Q1 of 2021 is most likely when the first data readout will happen. As we get nearer, we ought to be able to sharpen this timeline. Keep in mind that ORR is intended as an accelerated approval endpoint. Only a modest amount of alpha was spent on this, while PFS serves as the full approval endpoint; given the breakthrough designation, the doublet's potential in melanoma looks quite encouraging. Additionally, under our amended agreement with BMS, both of our companies are eager to broaden our development work into the adjuvant melanoma setting.
Howard Robin
executiveWhat this really means is that roughly twice as many individuals might see a benefit from this combination in melanoma, which is a major opening for BEMPEG. Since BMS holds the leading spot with nivolumab across every line of therapy in melanoma, we're happy that pairing BEMPEG with nivolumab could push the standard of care further in melanoma at both early and advanced stages. Turning to bladder cancer, we're currently running a trial of 200 patients in first-line cist-ineligible disease, and that study is meant to back a possible accelerated approval route in this setting. To be specific, this applies to those whose PD-L1 expression is low, defined as a CPS score below 10. We're looking for the first possible data on the ORR endpoint from this trial sometime in Q2 or Q3 of 2021, and to extend this bladder cancer opportunity, we've also kicked off a confirmatory Phase III trial in patients with cist-ineligible muscle-invasive bladder cancer. That allows us to seize the opportunity across both early and late-stage bladder cancer, widening what BEMPEG and NIVO might do for even more patients. When it comes to metastatic first-line renal cell carcinoma, BMS and Nektar picked a broad strategy that places the doublet in both a TKI sparing and a TKI inclusive regimen. Our Phase III Registrational Study testing BEMPEG and NIVO against a TKI in first-line RCC is enrolling well right now, and we remain on track for a possible first interim OS readout during the first quarter of 2022. Work on the TKI inclusive regimen is set to begin mid-year under the new BMS agreement, and it's built to support a Registrational path ahead in a first-line metastatic RCC study using this triplet; we'll carry out a Phase I/II dose escalation and expansion study to assess BEMPEG plus NIVO together with axi in first-line RCC so we can nail down the dose and administration schedule for a future Registrational Trial. Last, BMS and Nektar settled on a development path for the doublet in first line non-small cell lung cancer that we think sets BEMPEG up well for a flexible Registrational path ahead in non-small cell lung cancer. BMS will conduct a dose optimization and expansion study to pin down the right dose regimen, and BMS is covering 100% of that program's cost. Meanwhile we'll keep up our work testing pembro alongside BEMPEG in non-small cell lung cancer through our PROPEL trial, which is enrolling patients as we speak. Down the road, that leaves us room to consider proceeding with either NIVO or pembro in non-small cell lung cancer. We're glad the renewed agreement is now in place and we look forward to this stage of our collaboration; this structure also lifts certain exclusivity restrictions found in the old agreement covering a list of indications for BEMPEG, giving us greater flexibility to chase other combinations for BEMPEG. With that in mind, we're looking into what BEMPEG might do alongside other checkpoint inhibitors and other mechanisms, and growing that work is a key priority for us this year. Working together with Pfizer, we're running a Phase Ib/II study that's already underway in head and neck cancer as well as castration-resistant prostate cancer. That trial is going to assess BEMPEG and nivolumab in head and neck cancer, and it will also assess a pair of triplet regimens: BEMPEG plus avelumab plus talazoparib, and BEMPEG and avelumab and enzalutamide, in prostate cancer. Partnering with Pfizer on this has us really enthusiastic, given what's possible for BEMPEG across these two solid tumor settings, especially for patients whose tumors are PD-L1 negative. We've also launched a head and neck cancer study together with Vaccibody. That trial pairs BEMPEG with their personalized vaccine method, and it might open the door to a novel treatment regimen involving BEMPEG in this tumor setting. On top of that, we intend to begin a study with BioXcel that brings together their molecule, BEMPEG, and Pfizer, avelumab, in pancreatic cancer. As you can see, the BEMPEG program is shaping up as one of the biggest Registrational and development programs in immuno-oncology, and the possibility of this novel agent pairing with checkpoints and other mechanisms has us excited. Now to our next immuno-oncology candidate, NKTR-262, our TLR7/8 agonist: our Phase I/II REVEAL study keeps moving forward, and we recently reached our recommended Phase II dose of NKTR-262 together with BEMPEG. You'll remember that since this was a novel-novel combination, we needed to assess staged dosing of NKTR-262 with BEMPEG along with dose escalation. We have seen high levels of TLR activation within the tumor microenvironment, and the dose escalation lets us grasp PK/PD and then define safety for NKTR-262. Our present plan calls for taking the recommended Phase II dose of NKTR-262 into a focused expansion in at least one tumor type, beginning with 24 relapsed in refractory melanoma patients. On the basis of the biology behind innate and adaptive immune system interaction, we will now assess simultaneous dosing of the TLR and BEMPEG in order to explore what this combination might do in the IO relapsed/refractory melanoma setting. The scientific community is starting to appreciate how important natural killer cell biology is when treating cancer; and as many of you know, this research area is creating a great deal of excitement. Let me now move to our newest clinical candidate, our IL-15 agonist program called NKTR-255. NKTR-255 is built to capture the full biology of the IL-15 pathway so that it drives both proliferation of NK cells and the expansion of CD8 memory cells, which hands us a broad range of possible development pathways for NTKR-255. Considering the product profile, we're moving ahead on multiple fronts with this program, and JZ will give more details on the data coming out of this program, but let me offer a high-level overview of the progress on this promising mechanism. First, we're enrolling patients into our first-in-human clinical trial of NKTR 255, which got started last year. This study is looking at NKTR 255, initially on its own as a monotherapy, and afterward paired with dara or rituximab for multiple myeloma and non-Hodgkin's lymphoma, respectively; on top of that, two research collaborations are underway with partners who are covering all the research costs themselves. To start, Janssen is running preclinical work on NKTR-255, combining it with several of their in-house oncology mechanisms; and in a separate effort, within virology, Gilead is investigating what NKTR-255 might do in nonhuman primate studies, pairing it with a range of antivirals from their portfolio. So NKTR-255 could potentially have numerous uses in oncology and, possibly, virology too, and we're eager to see how it advances. Turning to NKTR-358, our Treg stimulatory program, which is partnered with Lilly. During 2019, last year, we announced substantial progress on this program. To begin, the human data from healthy volunteers came out at EULAR, and those data showed the candidate's dose-dependent and selected proliferation of Treg cells. We just finished the Phase Ib multiple ascending dose study in lupus patients, and those data have been submitted for presentation at this year's EULAR meeting. Lilly, our partner, also recently kicked off Phase Ib studies in 2 new autoimmune indications, psoriasis and atopic dermatitis, and those studies are continuing and bringing in patients.
Howard Robin
executiveLilly, our collaborator, intends to kick off a Phase II dose-ranging trial in lupus around the midpoint of this year, and they also expect to bring a second Phase II autoimmune indication into the development program during this year. So their dedication and the wide scope of this development effort make us quite happy, since it shows what this novel mechanism might be able to do for autoimmune diseases. Having said that, I'll hand things over to Wei so he can walk through the Phase III study design for BEMPEG. Wei?
Wei Lin
executiveThanks, Howard. I want to take a moment to walk through the broad strategy that we've put together alongside our partner, BMS, for the combination of the doublet with nivolumab in melanoma. That's a setting in which the IL-2 pathway has already been shown to work. As Howard mentioned, we've produced data in first-line metastatic melanoma from our pivotal Phase II trial of NPAC plus NIVO that is worthy of breakthrough designation. With a median follow-up of roughly 18 months, 34% of patients achieved a complete response, as assessed by blinded independent central review. In 42% of patients, hard lesions shrank by 100%, and 47% — nearly half — saw target lesions shrink by more than 75%. The importance of deep responses in metastatic melanoma and how they relate to survival was recently shown by the FDA in a meta-analysis presented at ASCO 2019. According to that analysis, patients whose RECIST target lesions shrank by 75% or more, including those who had a complete response, were very likely to experience the greatest gains in progression-free survival and overall survival, particularly when treated with immunotherapy. So response is clearly tied very strongly to survival in melanoma when IO agents are used. Against that backdrop, our pivotal Phase II data show that close to 1/2 of melanoma patients had a response of 75% or greater, which strengthens our confidence in the doublet for melanoma; and as we presented in November at SITC 2019, after approximately 18 months of follow-up, median PFS had not yet been reached. We intend to share updated data from this cohort at a future meeting during the second half of this year. Our confidence in the possible clinical benefit that BEMPEG plus NIVO could provide in melanoma has led us, together with BMS, to launch a study in the adjuvant setting. In this trial, we assess extended treatment of patients after surgery with BEMPEG plus NIVO, using event free survival as the endpoint. Treatment will last 12 months. We anticipate enrollment of between 900 and 1,000 patients, and the study will compare the BEMPEG plus NIVO doublet against single-agent nivolumab. We are in the process of finalizing the protocol with BMS and expect this trial to begin in the second half of this year. Because adjuvant melanoma studies run for a long time, we expect a possible first readout in 2024. With the Phase III metastatic melanoma study already underway and this new adjuvant study, BMS and Nektar now have a comprehensive approach to bringing the transformative potential of the BEMPEG/NIVO doublet to more melanoma patients. Also, as Howard said, in January, BMS launched the new Phase III bladder cancer study, which is enrolling patients who have muscle-invasive disease in the periadjuvant setting. Our ongoing metastatic study in urothelial carcinoma focuses on cisplatin-ineligible patients; this new Phase III trial brings our doublet into earlier disease for essentially the same patient population. The trial will also act as the confirmatory study for a possible accelerated approval filing that we plan alongside our ongoing metastatic trial. For the muscle-invasive trial, patients are going to be grouped based on their stage and PD-L one status. In the neoadjuvant pre-surgery segment, 540 patients get assigned randomly across three arms, receiving either BEMPEG in combination with NIVO, or NIVO by itself, or no therapy whatsoever — that last option being what's currently standard. Following cystectomy, they'll stay on that same pre-surgical regimen across a 12-month span. Pathologic complete response along with event-free survival will serve as the primary endpoints. Once more, this trial runs longer, and the earliest possible data readout is anticipated during 2024. Having said that, I'll pass things over to JZ, who can share more about our NTKR-255 program.
Jonathan Zalevsky
executiveAppreciate that, Wei. I'd like to spend a little more time discussing our IL-15 candidate, NKTR 255, given that it represents the next major cytokine asset in our pipeline and has been generating considerable attention. The design goal behind NKTR-255 was to encompass the complete biology associated with the IL-15 pathway. More specifically, by going after the IL-15 agonist pathway, NKTR-255 is engineered so that it captures each receptor-ligand interaction that can be accessed. As a result, NKTR-255 functions as a potent driver of natural killer cell expansion, and it also serves as an agent that promotes the survival and proliferation of memory CD8 T cells. There is growing recognition among researchers and clinicians regarding just how significant NK cells and memory cells are within the immuno-oncology cascade. As I said earlier, one thing that sets NKTR-255 apart is how we designed it to attach to every version of the IL-15 receptor, whereas other mutant proteins being developed latch onto beta gamma receptors alone. Our expectation is that this leads to better efficacy; for example, we understand that inducing intracellular granzyme B is necessary for NK cell-mediated cellular killing, and findings shared at SITC 2019 demonstrated that we reach peak granzyme B output compared with other muteins, and even surpass native IL-15. Beyond that, the preclinical results we have gathered thus far underscore the range of combination possibilities for this candidate. To start, one possibility we're looking at involves pairing our approach with antibodies like daratumumab and rituximab, both of which exert their effects through antibody-dependent cellular cytotoxicity, also known as ADCC. During that ADCC process, the antigen recognition portion of an antibody allows it to attach to the surface of a target cell. When antigen-recognizing antibodies coat a cell in this way, the resulting immune event is referred to as opsonization. NK cells then identify these opsonized cells when the Fc gamma receptors present on the NK cells attach to the Fc region of the antibodies sitting on those opsonized cells. Once those Fc gamma receptors cluster together, the NK cells undergo degranulation, which results in the destruction of the opsonized cells. So the targeted antibody can, in a selective and specific manner, opsonize cells through NK effector cell activity. That said, ADCC comes with a drawback: the NK cells — the effectors that drive killing of opsonized cells — get used up and depleted during the ADCC reaction. As a result, the targeted antibody's efficacy is limited. If NKTR-255 can boost NK cell proliferation and function, and we pair that with ADCC antibodies, the effect we observe could be quite profound. In nonclinical studies, NKTR-255 showed antitumor activity and greatly increased NK cell proliferation and activation in vivo, delivering sustained cytotoxic function. During the preclinical lymphoma study, daratumumab alone didn’t work, but when NKTR-255 was given together with daratumumab, it led to a rise in NK cell counts and activity within bone marrow tissue and improved ADCC-driven tumor cell removal in that same bone marrow area. That result is highly significant, because it confirmed NKTR-255’s ability to bring functional NK cells into the bone marrow compartment—demonstrating that with NKTR 255, the effects we can generate aren’t only systemic, but also depend on the tissue involved. More recently at ASH, we shared data showing that NKTR-255 increased both the number and the function of NK cells and CD8 effector memory T cell populations in peripheral blood samples from healthy donors and from multiple myeloma patients. On top of that, NKTR-255 may be able to flip NK cells back out of the suppressed condition seen in multiple myeloma patients. When given together with daratumumab and elotuzumab, it showed a synergistic effect, and it pushed up how susceptible the multiple myeloma cells were to NK activity by a marked degree, with that effect growing as the dose increased. All of this taken together gives us a solid rationale for our first clinical study, which has already begun. In that trial, we're looking at the safety profile and the dosing schedule for NKTR-255 given as a monotherapy, and after that we intend to move into combining it with antibodies that work via an ADCC mechanism, such as daratumumab and rituximab. For this study, the patients we plan to enroll are those with relapsed or refractory multiple myeloma along with non-Hodgkin's lymphoma. The trial will also look at pharmacokinetic and pharmacodynamic responses, plus any antitumor effects. On top of that, we've added a strong biomarker component to this study so we can get a thorough picture of how NKTR-255 behaves. In addition to NK cells, we're going to look at total counts and subsets of CD4 and CD8 memory T cells, which will let us examine what NKTR-255 does regarding their expansion, activation and survival. This biomarker-heavy strategy for early clinical development means we can let the science guide us as we work on and plan for NKTR 255. What we're shooting for is to have initial data from the first monotherapy portion of this Phase I trial within this year. On top of that, data from preclinical work on NKTR-255 could be shared by our partners Janssen and Gilead. We're also starting to see a role for NKTR-255 when paired with CAR-T and other cell-based treatments. CAR-T works really well, though its benefit tends to last only a fairly brief window. If we introduce IL-15 and encourage memory T cells to multiply, that might extend how long patients respond to CAR-T. And through our work with Fred Hutchinson, we've generated some striking early results that were also shown at ASH. To be more specific, the investigators showed that NKTR-255 stopped tumors from growing and boosted CAR-T cell survival in B-cell lymphoma models when combined with a CD19-targeted CAR-T cell treatment regimen. With that update, I'll hand things over to Gil, who will walk through the financials.
Gil Labrucherie
executiveThanks, JZ, and good afternoon to all of you. Earlier today, we put out our earnings press release covering the full year 2019 financial results, and during this call I'm going to walk you through our annual financial guidance for 2020. Let's begin with cash. We closed out 2019 holding $1.6 billion in cash and investments, and given how exceptionally strong that cash position is, we've made the decision to pay off the $250 million in senior secured notes still outstanding on our balance sheet. Doing so will make our balance sheet stronger and boost our yearly cash flow, since it should generate roughly $20 million in annual interest savings going forward. Regarding where our cash will go for operations and R&D, our estimate is a net cash outflow of approximately $350 million for 2020. That compares with $315 million of net cash used during 2019. The reason 2020's investment is larger is primarily our intention to complete patient enrollment for the first-line Registrational Studies covering melanoma, bladder, and renal cell carcinoma, plus our plan to launch the two additional Phase III trials beginning this year as part of the expanded BEMPEG development program under the BMS collaboration. After accounting for our intention to pay back the $250 million of debt during Q2, we anticipate ending 2020 holding about $1 billion in cash and investments. Let's now turn to revenue. For the year, our GAAP revenue guidance is a range of $140 million to $145 million. Included in that total is $50 million from BMS in the form of new and accelerated milestone payments under the expanded agreement we signed with them. Recognition of the initial $25 million tranche is set for Q1, linked to the MIBC study getting underway, which occurred in January. The remaining $25 million milestone is contingent on the adjuvant melanoma study beginning, and we currently expect that to happen in Q3. Beyond those milestones, the rest of our GAAP revenue—between $90 million and $95 million—should come in at a fairly even pace over 2020's four quarters. That breaks down as $40 million to $42 million from cash royalties, $34 million to $36 million in noncash royalty revenue, $11 million to $12 million from product sales, and another $5 million in other licensed collaboration revenue that isn't tied to BMS. For 2020, our GAAP R&D expense should land somewhere in the $475 million to $500 million range, and roughly $70 million of that reflects noncash depreciation along with stock compensation expense. Across the four quarters of this year, we'd expect that R&D expense to come in fairly ratable. Beyond what we're putting into R&D for the new trials under the expanded BMS collaboration, I want to highlight several other areas that will be key focuses for us in 2020. We need to hit our planned time line for the BLA filing and a possible commercial launch of BEMPEG in 2021. Also, this year we intend to finish validation of our large-scale commercial manufacturing process and start producing commercial supplies. As a result, BEMPEG production expenses are going to stay a big part of what we spend on R&D during 2020. Regarding the collaboration we have with BMS, they cover 35% of what it costs to manufacture BEMPEG. On top of that, we will continue funding BEMPEG development that sits outside the BMS partnership, and that includes the PROPEL trial we're running with pembrolizumab in non-small cell lung cancer. Through our collaborations with Pfizer, BioXcel and Vaccibody, we're also exploring combinations involving other modalities. Our R&D spending also covers kicking off two Phase II trials for NKTR-358s, plus the Phase IB trials in atopic dermatitis and psoriasis that are already underway. As Howard noted, we're launching the initial Phase II trial in lupus around the middle of this year. Meanwhile, a second Phase II trial, targeting an additional autoimmune condition, will begin during the latter portion of 2020. Remember that our Lilly partnership means we're responsible for 25% of those expenses. Beyond that, we'll continue providing funding for our Phase I/II programs involving NKTR-255 and NKTR-262. For 2020, we expect G&A costs to land somewhere between $105 million and $115 million, and that range accounts for approximately $45 million in noncash depreciation along with stock compensation expense. For 2020, GAAP interest income is projected to land somewhere between $30 million and $33 million. Once our senior notes are repaid, interest expense for the full year 2020 should total $7 million to $8 million, compared with $21.3 million during 2019. On top of that, we expect to record $26 million to $28 million of noncash interest expense associated with the legacy CIMZIA and MIRCERA. Turning to Q1 of this year, we plan to book an impairment charge of $45 million to $50 million on our income statement related to winding down the NKTR-181 program. That charge has two pieces: about $20 million in noncash charges, plus $25 million to $30 million of cash payments, largely connected to certain contract manufacturing commitments that cannot be canceled. As I mentioned before, we expect to close out 2020 with roughly $1 billion in cash and investments once our $250 million in senior secured notes are repaid. With that, we'll open the call for questions. Operator?
Chris Shibutani
analystThanks. Afternoon, everyone. Regarding the BEMPEG studies in lung, could you help us understand how patient accrual is going — for both the trial combining it with OPDIVO and the one with pembro? My understanding is there have been some challenges along the way historically. What steps have you taken that might be building greater confidence around your expected time lines?
Wei Lin
executiveHello, I'm Wei Lin, and I'll address that. As for our BEMPEG lung combination, like we mentioned earlier on this call, our approach truly involves two arms. One pairing is with pembrolizumab, and the other is with nivolumab. To begin with, the pembrolizumab pairing is the one Nektar is running. That trial, we anticipate, has begun enrolling patients. By the close of the year, we anticipate having data from 10 to 20 patients with adequate follow-up — no fewer than two scans — so we can evaluate activity. The nivolumab pairing is entirely run by BMS. That trial hasn't launched yet, and further specifics will come as the year progresses.
Jonathan Zalevsky
executiveChris, following up on 255 — the asset JZ mentioned — could you help us understand, perhaps give us a framework for, what sort of efficacy findings might emerge in the monotherapy setting for those 2 indications where we're probably going to get data, myeloma and so on? Absolutely. Chris, JZ here. We're going to be studying patients whose disease is quite advanced, since keep in mind this trial is first-in-human. As a result, we're escalating doses in the standard fashion, with modest patient counts at each dose level. And the patients we're treating have very advanced, late-line disease — something akin to a salvage regimen. So beyond any responses we might observe in these liquid tumor settings, we'll be tracking every possible outcome you can capture in a study like this within a first-in-human context. Chris is also going to be looking quite deeply into how IL-15 pathway agonism works mechanistically. That means we'll be examining cellular shifts throughout the body. We'll additionally be checking the tissue — in the bone marrow compartment, for instance — where we anticipate this mechanism of action will bring about further cellular changes. So our aim is to share the full picture of the results as best we can during this year.
Chris Shibutani
analystAlso, could you refresh my memory on how or where those data might be presented? Would it be during a medical meeting? Or are you going to top line it at the ASH?
Jonathan Zalevsky
executiveYeah, most probably it would be presented during a medical meeting. Yeah, that's right. So that's one good illustration. You could come up with a few other instances in which the emphasis is on liquid tumors.
Chris Shibutani
analystThat's excellent news, and we can't wait for the date on the 255 program. Thank you.
Alexander Duncan
analystHi, thanks for fielding the 255 program questions. Given the recent favorable IL-15 superagonist data in that area, have you had talks about evaluating 255 in bladder cancer as a doublet or a triple, and you're placing bigger bets on bladder with BEMPEG? And then, thinking more broadly about the platform, what makes you most confident that Nektar's compounds will be the optimal cytokine mimetics for combining down the road, as competitors and investment in this space keep growing?
Jonathan Zalevsky
executiveYes; so there are two questions there. Okay, starting with that first question. With NKTR-255, as you pointed out, we recognize this mechanism has quite a wide reach. It has many characteristics that don't overlap with IL-2 in terms of how it engages the pathway. You're able to use an IL-15 pathway agonist across a broad range — not just in liquid tumors, which is where the first-in-human study took place, but in solid tumor settings too. A number of tumors are known for having NK cell infiltrates, and bladder cancer is among them. Others exist that have some of the same features seen in GU tumor settings. So the opportunities for application are certainly very, very wide. Plus, 255 isn't the only factor here — the partners we choose to combine it with matter too. Take targeted therapy as an example of a combination partner: there's an enormously broad spectrum of those therapies spanning a great many tumor types, and that includes major indications such as breast cancer, where drugs like Herceptin are used, as well as every rituximab opportunity in B-cell NHL. So yes, when it comes to 255, we intend to pursue a very wide range of development possibilities. As for your second question, regarding the cytokines Nektar is working on — I'd say we've been given the opportunity to genuinely breathe new life into that area and build fresh momentum. When it comes to cytokines, the data we generated with BEMPEG speaks for itself. Naturally, we've used that as a foundation, pushing the BEMPEG program forward at a remarkably fast and forceful pace across several registrational settings. In doing so, we've effectively established a standard and an obstacle for the competitors trailing us. Our confidence in how we go after cytokines is strong, and thanks to our conjugation platform built on polymer chemistry, our molecules carry distinctive attributes designed into them. As for those rival companies lagging behind, they're forced to play catch-up with us on that front.
Alexander Duncan
analystThanks.
Jessica Fye
analystHi there. Evening, and I appreciate you taking my question. Could you discuss if you may decide to move the interim in the first-line Phase III melanoma trial to one that relies on complete response rate? Would the choice to make that change rest on FDA feedback that succeeding on CR could act as the foundation for accelerated approval? And if that's the case, have they provided any input on that point?
Wei Lin
executiveHello, this is Wei Lin. Yes, to a significant degree, the breakthrough designation we received in first-line melanoma rested, to a significant degree, on the pathologies, on the complete response observed in our pivotal two cohort. And I believe it was quite encouraging to use that endpoint when evaluating the quality and totality of our data. We are now in ongoing conversations with agencies, several agencies across the world. Concerning that endpoint as the initial endpoint to examine. And we'll give a further update once those regulatory discussions are finished. So at present, the formal first primary readout remains based on ORR.
Jessica Fye
analystGreat, thank you.
Bert Hazlett
analystThank you. Thanks for fielding the questions. I've got a couple. To start, it appears that in the Phase III first-line melanoma study, you'd aim to align patient characteristics with those of pivotal 2. Could you share any anecdotes showing you've managed that in the Phase III pivotal trial, compared with the PIVOT-02 data you've presented? And second, JZ, you brought up $262 million in the safety, could you share any features of that program's safety profile from Phase I.
Jonathan Zalevsky
executiveHey, Bert. JZ here. One thing we did within the PIVOT-02 cohort was ensure we enrolled patients whose baseline demographics and risk factors formed the same array. That corresponds to what you'd see in the Phase III population. Take liver metastases, for example — about a third of the people enrolled in PIVOT-02 arrived with those, and a similar share, roughly one in three, had LDH, or lactate dehydrogenase, readings that ran above the normal upper limit and fell into the M1c and M1b categories, which are tied to the grimmer or less favorable prognostic indicators among melanoma cases. Our reason for doing this was to make certain the group of patients matched the one in our Phase III. In fact, if you examine what BMS put out regarding CheckMate 067, the share of patients who had liver mets, raised LDH, or M1c status is really, really close to the makeup of our PIVOT-02 cohort. That's a crucial thing to bring up. I'm really glad you raised it. It mattered a great deal to us, since once we examined the full PIVOT-02 melanoma cohort results, two things stood out: first, presenting those results through blinded independent central review was essential to bolster the credibility of a single-arm study, and second, the patients enrolled in that cohort carried numerous unfavorable prognostic indicators. In our most recent update at SITC, we showed that complete responses occurred even among patients with liver metastases. So even in the toughest cases, in the most dire circumstances, a remarkably deep response was still seen, and this is in a patient group that mirrors the Phase III population. That really matters. Now, regarding what you asked next — you wanted to know about 262's safety profile. One key thing we did while creating 262 was to design a strategy for giving it directly into the tumor. Through our polymer conjugation approach, we extend how long the agent stays inside the tumor where it's injected. The purpose behind all of this is to keep systemic exposure as low as possible. Fortunately, since this targets TLR7/8, the underlying pathway is one we've accumulated substantial clinical familiarity with. What we can do is put the outcomes from our trial side by side with what one would anticipate when a TLR7/8 agonist is delivered through systemic infusion. As we showed in preclinical work, and as appeared in our toxicology findings and those of other groups, injecting directly into the tumor represents a very, very distinct and far better tolerated route for giving a TLR agonist. It is definitely much, much superior to systemic administration, which brings about enormous systemic cytokine consequences. When you inject into the tumor, everything stays highly localized, and that effect simply isn't observed.
Jonathan Zalevsky
executiveBert, thanks for the kind words — we're glad to hear it. Dr. Jonathan Zalevsky here, and yes, absolutely. Appreciate it, Bert.
Paul Choi
analystHello there, good afternoon to all of you. I appreciate you fielding our inquiries. There are a couple I'd like to raise. The initial one concerns the Phase III metastatic melanoma study and its scheduling. From what I can tell, the trial on ct.gov still shows that it's recruiting participants. Yet when I consider that you anticipate an interim data release during Q4, and bearing in mind what PIVOT-02 showed us — namely that reaching a complete response took roughly 8 months — could you offer some perspective on how we ought to interpret the kind of CR rates that might emerge? This is especially pertinent given what could constitute a threshold for how long patients must stay on treatment or be exposed to the drug throughout the applicable window.
Wei Lin
executiveAppreciate that inquiry, Paul. As was mentioned before, the endpoint concerning CR remains unchanged at this point; and CR, as you noted, has a median time to occurrence of roughly 7 months. Consequently, were we to conduct an analysis of CR, we'd want to track each patient across what would likely be a 10-month span. As a result, conversations will continue with the regulatory bodies about the number of subjects needed for registration predicated on the CR endpoint. And stemming from that, paired with an adequate duration, that combination would establish when the CR readout occurs, should that serve as the endpoint. Therefore, portions of this remain undetermined. Based on how we currently calculate it, the timing will likely land at approximately the same point as the overall ORR projection we have now. Naturally, all of this rests on present-day assumptions and without having completed the entire exchange with the health authority. So clarity on these matters should arrive over the next few months.
Paul Choi
analystAll right. Thank you for that, Wei. Then regarding 358, as you and Lilly, your partner, look into pushing this program forward across different dermatological indications, those spaces tend to be quite competitive. I suppose when you consider efficacy thresholds, whether for AD or other conditions, with the upcoming round of data updates, are you watching for specific measures or any elements of notable differentiation? Whatever insight you can share would be useful.
Jonathan Zalevsky
executiveCertainly. Hi, Paul. Right. This question is quite close to one you raised two days ago. So when it comes to the promising dermatological applications. Without a doubt, those benchmarks exist, correct? We recognize that treatments such as IL-23 and similar ones are establishing rather distinctive bars in those contexts. We know about them. Lilly knows about them. Therefore they serve as key reference points when evaluating the entire character of progress in dermatological indications. So that factor is constantly present. What's also challenging and truly essential is the fact that a novel mechanism is now being brought into this dermatological arena. Consequently, we actually understand there are even anticipations that Tregs will migrate into the skin in places where dysfunctional dermal cell growth occurs. As an illustration, we would anticipate the vulgar in psoriatic patients being infiltrated by Tregs, or an AD plaque likewise being infiltrated by Treg. Thus we will additionally be watching for that type of mechanism of action, since it contributes to that overall evaluation; and then another point is, bear in mind that with these sorts of diseases, you notice patterns of somewhat comparable autoimmune dysfunction. The tissue differs since tissues signify distinct forms of inflammation. Yet when it comes to the immunology, we observe parallels. In that sense, an indication such as atopic dermatitis matters greatly because numerous indications share a atopi as an underlying disease pathology driver. Not merely past atopic dermatitis. That is only a atopi within the skin, so we can likewise observe a topic in allergy and plenty of other sorts of contexts, correct? Past the dermal compartments. So those studies are extremely valuable, giving us both a feeling of opportunity inside those particular derm indications and also guidance on how to consider broadening the Treg mechanism even more extensively into the extra autoimmune themes addressed by those two indications.
Paul Choi
analystAppreciate you hosting the call.
George Farmer
analystHello, and thank you for fielding my questions. I want to dig deeper into the use of complete response as an endpoint for the Phase III melanoma trial. First off, does Bristol-Myers support this strategy? That's my first point; and second, how are you viewing the importance of CR? What gap must be bridged, in your view, to decide if the study ought to be filed for accelerated approval?
Wei Lin
executiveYes. To begin with, BMS is definitely our partner on this. We've talked about it at length. Given how enthusiastic the FDA has been regarding the CR endpoint, BMS likewise strongly agrees that this represents a legitimate endpoint worth pursuing. Now, regarding the threshold. The threshold is nivolumab, the comparator in our current trials, at roughly 8% to 9% with enough follow-up that we anticipate having when the readout occurs. That serves as the reference point. We will likely aim for an improvement of about 15%, which should suffice to rule out statistically the chance of a type one error; so at this moment, let me remind you, according to our pivot to data, our CR rate at approximately 18 months of follow-up stands at about 34%. And actually, even earlier at the 12-month follow-up mark, it was 34 per percent, correct? So that's the figure we're basing our projection on. Thus, at minimum, if we can reproduce what PIVOT-02 is showing, we hold a solid level of confidence that we can surpass the bar of doing better than this past year, as observed with nivolumab.
George Farmer
analystAll right. Yeah, that helps a lot. So when you eventually share additional PIVOT-02 data, do you believe we might get a look at overall survival findings from that trial?
Wei Lin
executiveAbsolutely. For PIVOT-02, in the melanoma cohort, we keep following patients — quite a few are still receiving treatment, and at minimum 2 patients could potentially shift from PR to CR. During the latter half of the year, we'd like to give an update on possibly 2 types of changes. The first is a deepening response in any patient who might move from PR to CR, plus a fresh estimate of what the possible PFS could look like. To remind everyone, after 18 months of follow-up, we still haven't determined the median progression-free survival. With extended follow-up, we can project an even greater PFS possibility. And again, nivolumab has roughly 7 months of PFS — 6 to 7 months of PFS. That's the standard we're comparing against in the study we're running now.
George Farmer
analystOkay, thanks. One more thing on NKTR-358 — since Lilly is pushing it into a Phase II trial for lupus, does that tell us the Phase Ib results look promising? Like, what made them decide to go ahead with that?
Jonathan Zalevsky
executiveHi George, JZ here. As you might remember, when we signed the deal with Lilly, the plan was for them to conduct at least four Phase II studies in various autoimmune conditions. We definitely did the Phase Ib — that was a multiple ascending dose trial in patients who had mild to moderate lupus — and if Lilly has wrapped that up, then this Phase II is clearly taking a closer look at the lupus patient population. Clearly, those patients will receive treatment over a far longer period than what's used in the multiple ascending dose trial. Beyond that, we're expanding into moderate to severe illness in pursuit of therapeutic benefit. So why focus on lupus? That's an excellent question you raised. In fact, lupus features a highly robust biomarker that regulatory T cells drive, which is where NKTR-358 comes in. Among lupus sufferers, there's a widely recognized and thoroughly documented impairment within their regulatory T cell compartment. This shows up in two distinct ways among patients with the disease, particularly those whose condition is progressing: first, a reduction in circulating Treg counts compared with healthy individuals—those without lupus—and second, diminished suppressive capability. If you take Tregs out of lupus patients and run them through a functional assay, their immunoregulatory performance comes out as very, very weak compared with what you see in Tregs taken from healthy donors. Those two things together make up a pair of central therapeutic themes, correct? — for bringing NKTR-358 and its mechanism of action into this disease. So we're also eager to share certain findings from the Phase Ib study in lupus patients before this year is over. An abstract has already gone to EULAR so that data can be presented; we're excited to provide an update coming out of that Phase Ib work, and we're even more excited about Lilly kicking off their Phase II study before this year ends.
George Farmer
analystThanks, JZ.
Jay Olson
analystAppreciate you taking my questions. Can you walk through the evidence supporting your choice to advance the doublet into muscle-invasive bladder cancer? And do you expect activity across the board, or would it depend on PD-L1 expression level, tumor mutational burden, or some other variable?
Wei Lin
executiveYes, this is Wei. Thanks for asking. The evidence behind our move into muscle-invasive bladder cancer is the very same dataset that underpins our work in metastatic disease. In the data we've already made public, we've in fact observed benefit among PD-L1 negative patients as well as positive ones. So it's open to anyone, meaning it doesn't matter what their PD-L1 status is, though it's restricted to patients who aren't eligible for cisplatin, which mirrors how we designed our metastatic trial.
Jay Olson
analystAll right, that's helpful. Now, when it comes to RCC, could you walk us through why you're going after a regimen that spares the TKI? Is the thinking that it may offer a better adverse event profile? Or is the goal better efficacy?
Wei Lin
executiveYes, the basis is definitely a better AE profile. As you're aware, rates of grade 3 adverse events — whether you're looking at avelumab plus axitinib or pembrol plus axitinib — are in fact extremely, extremely elevated; in fact, more than 50% of patients go through grade 3 or worse AEs while receiving the cellular treatment, and some stop treatment because of that. So, in order to truly deliver the greatest benefit, our expectation is that if we're able to keep a patient on the drug, that's one way to truly deliver the greatest benefit. Beyond that, when you use the TKI together with the checkpoint in a single regimen in the first-line setting, you essentially use up almost all of the therapy that's available. If instead we can put together a TKI-sparing regimen in the first line, then the physician and the patient still have a TKI option held in reserve, for the second line with later therapy. In my view, all of these things help patients. So there are several considerations behind our initial study, which really has been designed as PST caspin. Clearly, certain patients can't receive a TKI for a range of reasons. That's why we felt it was extremely important to give patients that choice, for all of these reasons.
Jay Olson
analystThat's really useful, thanks. We appreciate you fielding our questions.
Arlinda Lee
analystHey, everyone, and thanks for letting me ask. IL-15 caught my attention. It looks like quite a few other companies are in that area, with programs roughly heading into the clinic about now. I wanted to know what you'd point to as the main points of differentiation, and which early data we ought to watch to get a sense of how the competitive field is shaping up.
Jonathan Zalevsky
executiveAbsolutely. Hi, Arlinda — it's JZ here. One thing to keep in mind with IL-15 is that, similar to other cytokines in the IL-2 family such as IL-2, 15 and 7 — everything in that same class — their biology involves several receptor-ligand interactions. Typically there's a specific alpha receptor, correct? Then you also have a beta gamma receptor set that is common or shared. And gamma, as you're aware, is the common gamma chain, which is shared by more than 50 distinct cytokines that signal through it. So the way receptors and ligands interact, which cells carry the various receptor complexes, and every binding node — we think all of that matters a great deal. Specifically with IL-15, there are at minimum three binding modes: binding that depends on IL-15 alpha, and binding that doesn't. When it's independent, it behaves somewhat like a soluble ligand, engaging the IL-2 receptors beta and gamma, acting in a way that's sometimes described as a superagonist. Then there are two separate forms of IL-15 alpha dependent binding. The first occurs on the same cell — we refer to that as in sis — while on a different cell we call it in trans. The trans form matters especially, since cell-to-cell contact drives it. Much of IL-15 signaling happens at that contact interface, when one cell presents an alpha bound IL-15 molecule to a neighboring cell carrying beta gamma receptor complexes. Our molecule, NKTR-255, stands apart from every competing pipeline, because in each of those cases, IL-15 is complexed with the IL-15 receptor alpha. So the Altor molecule, SUNCOR and the rest, or Novartis and the Sushi Domains molecule — essentially they all rely on just a single primary binding mode, interacting only with the IL-2 receptor beta gamma. They cannot engage through either the sis or the trans alpha-dependent binding modes. NKTR-255, by contrast, retains every available receptor-ligand complex, and we intentionally designed it that way. So first, that's a scientific distinction at the receptor level. Beyond that, we've demonstrated what it means biologically: we're able to drive greater grandzyme induction, and we can drive interleukin 18 expression in CD14 monocytes — we've shared that data publicly — and those represent two activities that the receptor complexed versions of IL-15 targeting could not maintain. Another item that I believe deserves serious attention: when you observe signs of what you might call tachyphylaxis after administering multiple doses, does any biological effect diminish? That will be one more very significant area to examine, since in my view that is where something like NKTR-255 is going to set itself apart, given that it ought to show much, much less tachyphylaxis, or none at all, compared with certain other pipelines.
Arlinda Lee
analystCould that tachyphylaxis be something we'd see during Phase I?
Jonathan Zalevsky
executiveYes, indeed. Papers on other molecules exist — take, for instance, a paper on the outdoor molecule demonstrating that with repeat administration in patients, biological activity diminishes, particularly when it comes to cellular expansions, which those investigators quantified in the blood of people who received that molecule.
Arlinda Lee
analystThanks.
Andy Hseih
analystThanks, that's a good question. When it comes to RCC, it's fairly intriguing, since this is a front-line situation, and I believe CR is what pushes adoption; and if my memory serves, the CR rate in that RCC cohort came in at roughly 4%. So I'm just wondering — I suppose last year, as I recall, the company had intended to present data at ESMO. I'm just curious what the next steps are for releasing data from that cohort.
Wei Lin
executiveWell, we did share data during the previous earnings call, in the latter portion of it last year; so there hasn't been any fresh update on the RCC data. As a result, we have no plans for another presentation at a major medical congress regarding the RCC data, though we do ultimately intend to present it in the form of a manuscript.
Andy Hseih
analystUnderstood. All right, and to build a bit on what Bert asked regarding 262: is the thinking here that you could eventually pair 262 with BEMPEG as a salvage option — a checkpoint-less salvage regimen — across a range of solid tumors? Would that be an accurate way to put it?
Jonathan Zalevsky
executiveHi, this is JZ. Let's go back to when we first showed this program — we laid out the reasoning behind 262, which is about delivering an innate signal alongside BEMPEG, an adaptive signal, correct? That gives you a broad immune response. We also built it so that it's a fully owned doublet for Nektar. It was designed specifically and explicitly for use together with BEMPEG. As far as all the possible applications, the range is actually quite wide. We've decided to start clinical development by assessing activity in patients whose disease is very late stage. So, as you're aware, REVEAL functions somewhat like a basket trial, enrolling heavily pretreated patients with solid tumors across many different tumor types. That said, as we've noted, we intend to zero in on particular tumor types going forward, including melanoma in the relapsed/refractory setting. And you're aware we'll be testing the doublet, plus a triplet that adds a checkpoint inhibitor to the NKTR-262 plus BEMPEG combination. There's genuinely a great deal of potential for a combination like this. We'll be getting started, but as I said, our development begins in the relapsed/refractory setting. One thing we observed preclinically with this program — keep in mind it involved a very deep set of abscopal, immunological responses. We showed data, for instance, involving animals bearing multiple tumors. Yet you only had to inject a single tumor, and only once, to achieve the complete benefit of the immune reaction spreading through the animal's body and truly wiping out any tumor, regardless of its location, regardless of how far it sat from the tumor originally injected. In cancer immunotherapy, we refer to this as an abscopal, sort of, immune response. So once again, that was among the foundational visions behind the program. As we move into that setting and show the molecule can act that way, that could open up very broad usage and very broad opportunity for that regimen.
Andy Hseih
analystAll right, and regarding how we dose in non-small cell lung cancer. The bump in dosing compared with other pivotal trials — is that something unique to non-small cell lung cancer? Or what's your thinking on cross-indication differences when it comes to dosing?
Wei Lin
executiveYeah. A few considerations sit behind our strategy both to fine-tune our dose and to grow into non-small cell lung cancer. And of course, we remain confident in our 6-microgram per kilogram dose, which appears across all the Registrational Studies in melanoma, bladder cancer and RCC; all of that rests on PIVOT-02 data that allowed and led to the retraction trial alongside our partner, BMS; and in melanoma, for sure, the data supports a breakthrough designation; so the local activity is plainly present. As we examine the treatment landscape for non-small cell cancer along with the biology of the disease, plus the reality that monotherapy calls for a biomarker, all of this underscores the difficulty posed by non-small cell lung cancer and pushes us to ask whether another dose might deliver more benefit there. That's one thing; and the second is, because we've treated roughly 500 patients using nivolumab plus BEMPEG in combination, we've gained considerable knowledge about the safety profile of administering BEMPEG alongside nivolumab. And thanks to those lessons, we can manage the AE quite, quite effectively, far better than we could when the program first began. And with today's management guideline, we think we can actually give BEMPEG at a higher dose, and that's one more hypothesis we'd certainly like to test. That's also an additional motive for pursuing the dose optimization. So should we manage to reach a higher dose, then potentially the long Registrational Study would adopt that dose as we move ahead.
Andy Hseih
analystAll right. And one final thing for Gil. Could you just refresh our memory about the R&D reimbursement arrangement with Bristol? My understanding is that a limit exists — a yearly limit — and anything above it essentially gets paid back during the first quarter. So from a modeling perspective, how should we think about that as we move into Q1?
Gil Labrucherie
executiveYeah. You've got it right, Andy — a $125 million per year cap still applies to the sharing of R&D expenses under that agreement. That figure sits under GAAP revenue, and our expectation for this year is that we'll go past the cap near the end of the year. The way the agreement is structured, we'd receive reimbursement for going over the cap during the quarter that follows. So that cash would arrive in 2021.
Andy Hseih
analystAll right, that's excellent. I appreciate you taking all of my questions.
Daina Graybosch
analystThanks a lot for asking that. To start, I wanted to get something cleared up regarding the trial in early stage melanoma. Will it be testing treatment after surgery, or before surgery?
Wei Lin
executiveThe restoration study is designed as an adjuvant trial. It matches what's in the label right now for nivolumab, and that agent will be the control arm in this study.
Wei Lin
executiveDaina Graybosch asked a follow-up question about melanoma. She noted that in the neoadjuvant setting, immunotherapy has shown pretty remarkable results, especially when used in combination but also with a single agent. She wanted to know whether he worries that this kind of benefit could be overlooked. She also asked whether the patients in this case are receiving NIVO by itself in the neoadjuvant setting. Dr. Wei Lin replied that this is definitely something that could happen. He explained that what's used in current standard practice — well, actually, there is no standard of care here, since nothing has been approved for the neoadjuvant setting, given that most of these data come from extremely small patient cohorts, really only in the teens. So to get the green light in the neoadjuvant indication, you'd need a completely randomized study — that's exactly the pathway the adjuvant trial followed. And as things stand, none of the sponsors are currently trying to launch a trial of that size, because the adjuvant setting already has an accepted standard of care. That means certain academic institutions might adopt this approach in practice, and a few doctors could choose to give their own patients neoadjuvant treatment when the patient fits certain criteria. Still, my sense is that neoadjuvant won't become the main way this is handled clinically. So for the foreseeable future — and definitely within the period before our study reports results — we don't see re neoadjuvant replacing adjuvant as the standard of care.
Wei Lin
executiveThanks for that. My second question goes back to CR as a possible endpoint in the frontline metastatic melanoma trial. It's fascinating, since typically response rate shows up quite fast. You capture a snapshot after a certain period of follow-up. Yet I believe we're all aware that with melanoma, when you examine the CR rate at three or four years, it keeps deepening on nivolumab or pembrolizumab as monotherapy. So I'm curious how you're approaching this — would the data need to mature over time, with an interim read, while also assessing the CRA comparison across several years? Yes. Our confidence in possibly using CR as the foundation for approval certainly rests on our PIVOT-02 data, as has been noted before. Our time to CR is in fact seven months. So that's actually relatively fast. I recognize that based on CheckMate 67, there is extremely long follow-up, reaching up to five years. And it's accurate that as follow-up extends, the CR does deepen over time. Yet even when you examine the nivolumab and NIVO/ipi data, with extended follow-up, even beyond four to five years of follow-up, NIVO has not reached a CR above 20%. And NIVO plus ipi has seldom reached a CR rate of 21%, which differs greatly from what we could achieve with only a bit more than a year of follow-up at 34%. So that truly is the distinguishing factor, correct? And so the rate of CR that BEMPEG plus nivolumab has managed to achieve in the PIVOT-02 study is much faster. And I think across the follow-up period, even with what we intend to be a 10-month follow, we believe we can genuinely set ourselves apart from the nivolumab control arm.
Daina Graybosch
analystThank you. For JZ, one final item regarding NKTR 255. Many patients, particularly those with hematological malignancies, are known to have NK cells that are either worn out or not working properly. So I'd like to know whether NKTR-255 is able to bring back their function and their perforation too?
Jonathan Zalevsky
executiveYes, that is absolutely among the aspects we are extremely, extremely eager to examine; and that's partly why the initial patient group. In our trial consists of advanced-stage NHL patients, and specifically, advanced-stage multiple myeloma patients. Dana, you're very aware, correct, especially in multiple myeloma, particularly in multiple myeloma. There is enormous, and potentially devastating, impairment within the NK cell compartment, in terms of both cells possessing weak effector status — affecting their capacity to keep degranulating — and declining cell counts. And also, for instance, even following treatments such as dara, for instance, or any CD38 that further reduces these cells too; so without question, that's among the first biomarkers we are evaluating in our clinical study. As you're aware, when using these cytokines, we constantly assess systemic cellular alterations. And since it's a measurement from blood in the central compartment, it's highly reliable and simple to assess; so it's unquestionably a central element of our biomarker efforts and our mechanism of action evaluation for NKTR-255.
Daina Graybosch
analystThank you, that's great.
Howard Robin
executiveAll right. So, I appreciate all of you being with us here today. And, as we always do, I want to express gratitude to the people who work for us for everything they put in and their dedication to this organization. Here at Nektar, we've genuinely assembled an extremely valuable set of programs spanning immuno-oncology as well as immunology. And our efforts have truly been aimed at big patient groups in which a great many individuals deal with severe illness and face a substantial unmet medical need — in solid and liquid tumors, across a wide range of possible treatment indications, and in autoimmune disease, spanning numerous autoimmune and chronic inflammatory conditions. So we're eager to move these programs forward, to keep giving you updates on how we're growing, and we can't wait to see a lot of you at the conferences coming up in the next few months. So, many thanks for being here with us today, and we hope to see you soon. Thank you.
Operator
operatorThank you, everyone, for taking part in this call. That brings the session to a close, so you're free to hang up now. Have a great day, all of you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.